PTIX (Protagenic Therapeutics) EPS (Basic) : $-1.27 (TTM As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics EPS (Basic)?

Protagenic Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Sep. 2024 was $-0.14. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.27.

Protagenic Therapeutics's EPS (Diluted) for the three months ended in Sep. 2024 was $-0.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.27.

Protagenic Therapeutics's EPS without NRI for the three months ended in Sep. 2024 was $-0.14. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2024 was -1.17.

During the past 3 years, the average EPS without NRI Growth Rate was 2.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -1.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was 44.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Protagenic Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 92.70% per year. The lowest was -680.30% per year. And the median was 9.50% per year.

Protagenic Therapeutics EPS (Basic) Historical Data

The historical data trend for Protagenic Therapeutics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics EPS (Basic) Chart

Protagenic Therapeutics Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.68

-1.00

-1.24

-0.82

-1.15

Protagenic Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EPS (Basic)	Get a 7-Day Free Trial															-0.32	-0.38	-0.39	-0.36	-0.14

Protagenic Therapeutics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Protagenic Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-5	-	0)	/	4.345
	=	-1.15

Protagenic Therapeutics's Basic EPS for the quarter that ended in Sep. 2024 is calculated as

Basic EPS (Q: Sep. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.641	-	0)	/	4.529
	=	-0.14

EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.27

Protagenic Therapeutics (NAS:PTIX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Protagenic Therapeutics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagenic Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.protagenic.com

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Executives

Alexander K. Arrow	officer: Chief Financial Officer	PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell	director	3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein	director	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan	officer: COO / Interim President	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen	director, 10 percent owner, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea	director, officer: Chief Executive Officer	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin	officer: Chief Financial Officer	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong	officer: Chief Financial Officer	THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel	officer: Chief Marketing Officer	C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci	director, officer: Exec VP, Corporate Development	C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367